Sales of Seattle Genetics Inc.’s new bladder cancer drug Padcev (enfortumab vedotin), developed in partnership with Astellas Pharma Inc., brought in an impressive $34.5m in sales during its first full quarter on the market in the US, far exceeding analyst consensus of $7.8m for Q1. As Seattle Genetics reported its first quarter earnings on 30 April, the company outlined the path for expanding the indications for the antibody-drug conjugate (ADC) targeting Nectin-4.
The US Food and Drug Administration approved Padcev in December to treat locally advanced or metastatic urothelial cancer patients who...